Skip to main content
S

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 809 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于参加十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会暨2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement by Shanghai Medicilon about its participation in a 2025 annual and 2026 Q1 performance explanation meeting (业绩说明会). It does not contain actual financial results (so it is not an Earnings Release (ER)), nor is it the full annual or interim report itself. It is not a publication of a report (so not RPA) but rather a notice of an upcoming investor event. Since there is no dedicated “meeting notice” category, this falls into the miscellaneous Regulatory Filings (RNS) bucket.
2026-04-22 Chinese
美迪西：审计报告及财务报表二〇二五年度
Audit Report / Information Classification · 1% confidence The document is a standalone audit report (“审计报告”) issued by BDO China, covering the 2025 audit opinion and including the audited financial statements (balance sheets, income statements, cash flows, notes). It does not include broader annual report narrative or management discussion, nor is it an announcement of a report. This aligns with a standalone Audit Report category.
2026-04-22 Chinese
美迪西：立信会计师事务所（特殊普通合伙）关于公司2025年度非经营性资金占用及其他关联资金往来情况的专项报告
Audit Report / Information Classification · 1% confidence The document is a standalone auditor’s special audit report (“专项审计报告”) on non-operating fund occupancy and related-party transactions for the 2025 fiscal year, prepared by an accounting firm and including audit opinions and detailed schedules. It is not a full annual report, nor merely an announcement; it is a specific audit report. Hence, it falls under the Audit Report / Information category (AR).
2026-04-22 Chinese
美迪西：关于修订和制定公司部分治理制度的公告
Governance Information Classification · 1% confidence The document is an announcement by Shanghai Medicilon Biopharmaceutical detailing revisions and new formulations of internal governance systems (director/shareholding management, compensation management, hedging business management). It is not an earnings release, proxy statement, or management change notice but specifically pertains to corporate governance rules and procedures. This matches the definition of Governance Information (CGR).
2026-04-22 Chinese
美迪西：2025年度独立董事述职报告（王剑锋）
Governance Information Classification · 1% confidence The document is the 2025 annual performance report (“述职报告”) by an independent director, detailing his board attendance, committee work, governance oversight, compliance with laws and regulations, and communication with auditors and shareholders. It is not announcing new financial results, share transactions, or an annual report. Rather, it focuses on governance practice and board oversight functions. The best match from the predefined categories is Governance Information (CGR).
2026-04-22 Chinese
美迪西：2025年度独立董事述职报告（马大为-已离任）
Governance Information Classification · 1% confidence The document is an annual “Independent Director’s Work Report” (2025年度独立董事述职报告) produced by the company’s independent director. It details board attendance, committee activities, oversight of financial statements, related-party transactions, audit interactions and governance practices throughout the year. It is not a financial report (no financial statements), not an earnings release or change announcement, but a standalone governance compliance document focused on board structure, internal rules and governance oversight. Therefore it falls under the Governance Information category (CGR).
2026-04-22 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.